Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice

Ottaiano, A; Capozzi, M; Tafuto, S; De Stefano, A; De Divitiis, C; Romano, C; Avallone, A; Nasti, G

Ottaiano, A (reprint author), SSD Innovat Therapy Abdominal Metastases, Naples, Italy.

FRONTIERS IN ONCOLOGY, 2019; 9 ():

Abstract

Background: There are no clinical studies comparing the efficacy of bevacizumab vs.aflibercept in association with folfiri in RAS mutated (RAS-M) meta......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索